Breast cancer is cancer that effects the breast tissue. Breast cancer is the most commonly diagnosed cancer among American women, besides skin cancer. Currently, to treat breast cancer various drugs like hormonal treatment, HER2 receptor-based drugs are available in the market. However, these drugs will not act against on triple-negative breast cancers this is mainly due to absence of receptors in triple-negative breast cancer conditions. Usually, in breast cancer cells they have receptors on their surface for HER2 protein, estrogen and progesterone hormones. If the breast cancer test shows positive for these receptors, it signifies breast cancer cells have receptors for estrogen, progesterone, and HER2 protein. These receptors are responsible for the growth of cancer. However, these receptors are absent in triple-negative breast cancer conditions. Hence, triple breast cancer can’t be treat with targeted therapies such as aromatase inhibitors and hormonal based therapies. Till date, there were no specific drugs in the market that can treat triple-negative breast cancer – leaving patients with fewer options by treating with surgery, radiotherapy and chemotherapy. In most of the cases, after performing surgery chemotherapy treatment is given – adjuvant chemotherapy. In some cases, chemotherapy is given before surgery – neoadjuvant chemotherapy. In this treatment procedure, it helps in reduction of tumor size of breast cancer. About 10-20% of breast cancers cases are triple-negative breast cancers. Unmet need of triple-negative breast cancer is lack of proper interventions and treatment protocols. Few companies are trying to develop molecules that can treat triple-negative breast cancer conditions. For instance, Eribulin mesylate (Halaven®), developed by Eisai, completed clinical trials Phase 3 studies to treat triple-negative breast cancer conditions. In February 2016, Sacituzumab Govitecan (IMMU-132) got U.S. FDA breakthrough therapy designation for its treatment of triple-negative breast cancer conditions. IMMU-132 is an antibody-drug conjugate that acts by binding to protein Trop2 that overexpresses in triple breast cancer. Various other molecules are currently undergoing clinical trials to treat triple negative breast cancer.
According to the research article published in Journal of the Moffitt Cancer Center, around 1 million breast cancers are diagnosed globally among them 1.7% of cancer cases are triple-negative cancers. Triple-negative breast cancers are more aggressive and fewer survival rates when compared with breast cancer. Increase in incidence of breast cancers globally, and higher mortality rates related to breast cancers in developing countries are projected to driving the growth of this market during the forecast period. Lack of treatment regimens and proper drugs to treat this condition are hindering growth of this market.
Therapeutic area of triple-negative breast cancer treatment market was segmented into alkylating agents, natural products, antimetabolites and microtubule stabilizing agents. Alkylating agents is further segmented into Platinum coordination complexes. Natural products category is segmented into Plant products and Microorganism products.
Based on the route of administration, the triple-negative breast cancer treatment market was segmented into oral and parenteral. Parenteral route occupies the major market share followed by the oral route.
On the basis of the distribution channel, triple-negative breast cancer treatment market is segmented into hospital and retail pharmacies Hospital pharmacies accounts largest market share due to availability of these drugs in hospitals to treat breast cancer
Based on the geographic region, triple-negative breast cancer treatment market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. North America occupies the major market share due to high research activities on triple-negative breast cancer, buying power of patients are the major factors boosting the growth of this market during the forecast period. Asia Pacific region is expected to grow with highest CAGR over the forecast period due to high incidence and mortality rates of breast cancer condition in this region.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14305
Some of the players in triple-negative breast cancer treatment market include Celgene, Roche, Immunomedics GmbH, Merck & Co., Inc., F. Hoffmann-La Roche Ltd and Eisai Co., Ltd.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/14305
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353